Myriad Genetics Inc. (MYGN)
MYGN trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$4.08
-2.86% on the day
Market cap
$390.3M
Small cap
Revenue · 2025
$824.5M
-1.6% on 2024
Net income · 2025
-$366.0M
-44.4% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | MYGN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Country | United States |
| IPO year | 1995 |
| SEC CIK | 0000899923 |
| SEC industry code | In Vitro & In Vivo Diagnostic Substances |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $824.5M |
| Net income | -$366.0M |
| Operating income | -$387.2M |
| Net margin | -44.4% |
| Operating margin | -47.0% |
| Revenue growth | -1.6% |
| Cash | $149.6M |
| Total assets | $706.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.5× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-03-04 |
| Latest annual report | 10-K | 2026-02-24 |
| Latest quarterly / interim | 10-Q | 2026-07-31 |
| Latest current report | 8-K | 2026-10-09 |
| Latest proxy | DEFA14A | 2026-04-14 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.2% |
| 1 month | +9.0% |
| 3 months | -31.7% |
| Year to date | -31.2% |
| 1 year | -46.0% |
| From 52-week high | -48.3% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TKNO | Alpha Teknova Inc. | $8.22 | -5.52% | $441.3M |
| NNNN | Anbio Biotechnology | $4.26 | -3.40% | $613.0M |
| ACHV | Achieve Life Sciences Inc. Common Shares | $7.00 | -0.85% | $720.3M |
| QDEL | QuidelOrtho Corporation | $14.10 | +6.42% | $966.9M |
| ICCC | ImmuCell Corporation | $10.79 | +12.40% | $98.0M |
| IMDX | Insight Molecular Diagnostics Inc. | $2.99 | -5.68% | $97.8M |
| NTLA | Intellia Therapeutics Inc. | $11.91 | -5.33% | $1.7B |
| CLDX | Celldex Therapeutics Inc. | $28.25 | -4.01% | $2.2B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier